Keeping the strategy contemporary and relevant

In keeping with the MS Research Australia three year Strategic Plan, an independent Leadership Council has been established. The Leadership Council will be consulted to ensure that the strategy is kept contemporary and relevant. This small group of national leaders based in Australia and internationally represent a variety of backgrounds and will lend immense support and guidance to the MS Research Australia team. They will help to identify trends and influences in the Australian and international corporate, political and philanthropic markets.

All members bring unique business knowledge and experience, together with an affinity for the non-for-profit sector and MS, which complement the knowledge and skills of the board members and the MS Research Australia executive team.

A small sub-group of our international based members, including Lisa Pettigrew, Chris Benscher and Cassandra Kelly have already been incredibly supportive with our global work via the International Progressive MS Alliance: offering advice, overseas networks and giving their time by attending important events. These members also assisted with the global roll out of the Kiss Goodbye to MS initiative which was launched in January this year. The Australian founded campaign raising funds for MS research, has been taken up by nine other countries so far including the United States.

We are extremely privileged and grateful to be able to work with the Leadership Council who have all committed to supporting us in achieving the goals of MS Research Australia.

Leadership Council


Dr Burke’s Australia Day Honour puts multiple sclerosis in the spotlight

MS Australia congratulates Dr Therese Burke who has been honoured for her significant service to medicine, particularly multiple sclerosis research, and to nursing, by being made a Member of the Order of Australia (AM) in today’s 2023 Australia Day Honours List.
Red and white blood cells

Cladribine restricts immune cells from entering the brain

As well as depleting immune cells, new research shows cladribine (Mavenclad) may impede their movement into brain tissue, preventing further damage by multiple sclerosis.

What us to keep you in the loop? Subscribe today!

  • Enter your details

Read More

Newsletter subscription

  • Enter your details

Keeping the strategy contemporary and relevant